-+ 0.00%
-+ 0.00%
-+ 0.00%

NEUROSENSE THERAPEUTICS - PRIMEC SHOWS SIGNIFICANT TDP-43 REDUCTION AT DAY 180 AND DAY 540 IN PHASE 2B ALS STUDY

Reuters·06/29/2026 13:30:01

Please log in to view news